Dupixent® (dupilumab) significantly reduced copd exacerbations in second positive phase 3 trial, accelerating fda submission and confirming potential to become first approved biologic for this serious disease

Notus trial met its primary endpoint with overwhelming efficacy, showing dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe copd with evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per Μl), confirming results from the landmark boreas pivotal trial
REGN Ratings Summary
REGN Quant Ranking